Laura Adams National Academy of Medicine

Laura Adams, MS, Senior Advisor at the National Academy of Medicine (NAM), provides strategic leadership for the Science and Technology portfolio and leads the NAM’s Artificial Intelligence Code of Conduct national initiative. Laura chairs the Global Opportunities Group for the AI Regulatory Science and Innovation Network in the UK, and she is a strategic advisor for Inflammatix, a Burlingame, CA-based biotech company specializing in host immune response diagnostics. Laura is a member of the international AI Expert Panel for the Organization of Economic Co-operation and Development (OECD); the Bipartisan Policy Center’s Health Care AI Advisory Panel, and Consumer Technology Association’s Health AI Planning Council. She is recognized as a strategic leader of large scale multisectoral initiatives with a deep experience in and understanding of the complex U.S. health care industry, including how the components function and interact. She chaired the Institute of Medicine’s (IOM) Digital Infrastructure for the Learning Healthcare System initiative and was among the first to bring the science of healthcare quality improvement to the Middle East, in conjunction with the Harvard Institute for Social and Economic Policy in the Middle East. She served as Institute for Healthcare Improvement (IHI) faculty at the inaugural IHI Middle East Forum on Quality Improvement in Healthcare in Doha, Qatar. Prior to her work at the NAM, Laura was founding President and CEO of the Rhode Island Quality Institute (RIQI), a statewide health information exchange. Under her leadership, RIQI won the National Council for Community Behavioral Health Excellence Award for Impact on those with behavioral health and substance abuse challenges. RIQI was the recipient of the national Healthcare Informatics Innovation Award; and a top finalist for the New England Business Innovation award for impact on the opioid crisis. Laura has delivered keynotes in nearly every US state and in 13 foreign countries.